MYOS (NASDAQ: MYOS) is one of 531 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare MYOS to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, valuation and dividends.
Earnings and Valuation
This table compares MYOS and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MYOS Competitors||$2.18 billion||$164.12 million||-1.82|
MYOS’s peers have higher revenue and earnings than MYOS. MYOS is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares MYOS and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
1.7% of MYOS shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 47.3% of MYOS shares are owned by company insiders. Comparatively, 15.3% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent recommendations for MYOS and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Pharmaceutical preparations” companies have a potential upside of 69.28%. Given MYOS’s peers higher probable upside, analysts clearly believe MYOS has less favorable growth aspects than its peers.
Risk and Volatility
MYOS has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, MYOS’s peers have a beta of 1.16, indicating that their average stock price is 16% more volatile than the S&P 500.
MYOS peers beat MYOS on 7 of the 10 factors compared.
MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of FortetropinÂ on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with MarketBeat.com's FREE daily email newsletter.